Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


15.10.2018

1 Am J Surg Pathol
2 Ann Oncol
3 Ann Surg
7 Ann Surg Oncol
3 BMC Cancer
1 BMJ
3 Br J Cancer
3 Breast Cancer
4 Breast Cancer Res
6 Breast Cancer Res Treat
3 Breast J
5 Cancer
2 Cancer Res
3 Clin Breast Cancer
1 Clin Cancer Res
1 Eur J Cancer
1 Gene
1 Histopathology
4 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
4 J Natl Cancer Inst
1 J Surg Oncol
1 N Engl J Med
1 Oncology
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg Pathol

  1. STEINER DF, MacDonald R, Liu Y, Truszkowski P, et al
    Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer.
    Am J Surg Pathol. 2018 Oct 12. doi: 10.1097/PAS.0000000000001151.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    PubMed     Text format    

  3. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg

  4. SIMONS JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, et al
    Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Ann Surg. 2018 Oct 11. doi: 10.1097/SLA.0000000000003075.
    PubMed     Text format     Abstract available

  5. LOHMANDER F, Lagergren J, Roy PG, Johansson H, et al
    Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment.
    Ann Surg. 2018 Oct 10. doi: 10.1097/SLA.0000000000003054.
    PubMed     Text format     Abstract available

  6. PLICHTA JK, Ren Y, Thomas SM, Greenup RA, et al
    Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual.
    Ann Surg. 2018 Oct 11. doi: 10.1097/SLA.0000000000003071.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  7. LANG JE, Brownson KE
    ASO Author Reflections: The Whole Transcriptome Landscape of Circulating Tumor Cells in Nonmetastatic Breast Cancer.
    Ann Surg Oncol. 2018 Oct 11. pii: 10.1245/s10434-018-6888.
    PubMed     Text format    

  8. RUBIO IT
    ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer.
    Ann Surg Oncol. 2018 Oct 3. pii: 10.1245/s10434-018-6849.
    PubMed     Text format    

  9. SCHWARTZBERG B, Lewin J, Abdelatif O, Bernard J, et al
    Correction to: Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations.
    Ann Surg Oncol. 2018 Oct 8. pii: 10.1245/s10434-018-6861.
    PubMed     Text format     Abstract available

  10. CRONIN PA, Romanoff A, Zabor EC, Stempel M, et al
    Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.
    Ann Surg Oncol. 2018 Oct 8. pii: 10.1245/s10434-018-6767.
    PubMed     Text format     Abstract available

  11. JAMES TA
    ASO Author Reflections: Addressing Surgery-Specific Risk Factors Influencing Time to Chemotherapy in Breast Cancer.
    Ann Surg Oncol. 2018 Oct 9. pii: 10.1245/s10434-018-6852.
    PubMed     Text format    

  12. LAIRD J, Braunstein LZ
    ASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications.
    Ann Surg Oncol. 2018 Oct 10. pii: 10.1245/s10434-018-6889.
    PubMed     Text format    

  13. KAWAGUCHI T, Yan L, Qi Q, Peng X, et al
    Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.
    Ann Surg Oncol. 2018 Oct 11. pii: 10.1245/s10434-018-6859.
    PubMed     Text format     Abstract available


    BMC Cancer

  14. GHOREISHI Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, et al
    Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    BMC Cancer. 2018;18:958.
    PubMed     Text format     Abstract available

  15. LEE KH, Kim EY, Yun JS, Park YL, et al
    The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
    BMC Cancer. 2018;18:938.
    PubMed     Text format     Abstract available

  16. EUSTACE AJ, Conlon NT, McDermott MSJ, Browne BC, et al
    Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    BMC Cancer. 2018;18:965.
    PubMed     Text format     Abstract available


    BMJ

  17. MATTHEWS A, Stanway S, Farmer RE, Strongman H, et al
    Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
    BMJ. 2018;363:k3845.
    PubMed     Text format     Abstract available


    Br J Cancer

  18. STEVENS RG
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 Oct 3. pii: 10.1038/s41416-018-0058.
    PubMed     Text format    

  19. KRUGER DT, Beelen KJ, Opdam M, Sanders J, et al
    Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0221.
    PubMed     Text format     Abstract available

  20. BAJOR M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, et al
    Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0263.
    PubMed     Text format     Abstract available


    Breast Cancer

  21. SAIMURA M, Koga K, Anan K, Mitsuyama S, et al
    Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors.
    Breast Cancer. 2018;25:470-478.
    PubMed     Text format     Abstract available

  22. MACHIDA Y, Shimauchi A, Igarashi T, Hoshi K, et al
    Preoperative breast MRI: reproducibility and significance of findings relevant to nipple-areolar complex involvement.
    Breast Cancer. 2018;25:456-463.
    PubMed     Text format     Abstract available

  23. HASHEMI ZS, Forouzandeh Moghadam M, Khalili S, Ghavami M, et al
    Additive effect of metastamiR-193b and breast cancer metastasis suppressor 1 as an anti-metastatic strategy.
    Breast Cancer. 2018 Oct 3. pii: 10.1007/s12282-018-0915.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  24. SETHURAMAN A, Brown M, Krutilina R, Wu ZH, et al
    BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion.
    Breast Cancer Res. 2018;20:117.
    PubMed     Text format     Abstract available

  25. SWERDLOW AJ, Wright LB, Schoemaker MJ, Jones ME, et al
    Maternal breast cancer risk in relation to birthweight and gestation of her offspring.
    Breast Cancer Res. 2018;20:110.
    PubMed     Text format     Abstract available

  26. UNGERLEIDER NA, Rao SG, Shahbandi A, Yee D, et al
    Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    Breast Cancer Res. 2018;20:115.
    PubMed     Text format     Abstract available

  27. ANDERSEN ZJ, Jorgensen JT, Elsborg L, Lophaven SN, et al
    Long-term exposure to road traffic noise and incidence of breast cancer: a cohort study.
    Breast Cancer Res. 2018;20:119.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  28. REN JX, Gong Y, Ling H, Hu X, et al
    Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics.
    Breast Cancer Res Treat. 2018 Oct 6. pii: 10.1007/s10549-018-4956.
    PubMed     Text format     Abstract available

  29. KRAMER CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, et al
    The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
    Breast Cancer Res Treat. 2018 Oct 9. pii: 10.1007/s10549-018-4987.
    PubMed     Text format     Abstract available

  30. ALFARSI LH, Elansari R, Toss MS, Diez-Rodriguez M, et al
    Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4978.
    PubMed     Text format     Abstract available

  31. GUESTINI F, Ono K, Miyashita M, Ishida T, et al
    Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4985.
    PubMed     Text format     Abstract available

  32. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Oct 11. pii: 10.1007/s10549-018-4975.
    PubMed     Text format     Abstract available

  33. KUSSAIBI H, Alkharsah KR, Altamimi D, Alsayyah A, et al
    Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4999.
    PubMed     Text format     Abstract available


    Breast J

  34. MAZOUNI C, Koual M, De Leeuw F, Conversano A, et al
    Prospective evaluation of the limitations of near-infrared imaging in detecting axillary sentinel lymph nodes in primary breast cancer.
    Breast J. 2018 Oct 8. doi: 10.1111/tbj.13123.
    PubMed     Text format     Abstract available

  35. SURMELI ZG
    Primary tumor resection in metastatic breast cancer: A propensity-matched analysis, 1988-2011 SEER data base.
    Breast J. 2018 Oct 7. doi: 10.1111/tbj.13145.
    PubMed     Text format    

  36. CROCE MV, Cermignani L, Rabassa ME, Segal-Eiras A, et al
    Factors associated with breast cancer in an Argentine city.
    Breast J. 2018 Oct 4. doi: 10.1111/tbj.13147.
    PubMed     Text format    


    Cancer

  37. ANDERSON C, Nichols HB, Deal AM, Mark Park YM, et al
    Changes in cardiovascular disease risk and risk factors among women with and without breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31775.
    PubMed     Text format     Abstract available

  38. PERNAS S, Barroso-Sousa R, Tolaney SM
    Optimal treatment of early stage HER2-positive breast cancer.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31657.
    PubMed     Text format     Abstract available

  39. GORNICK MC, Kurian AW, An LC, Fagerlin A, et al
    Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.
    Cancer. 2018 Oct 5. doi: 10.1002/cncr.31731.
    PubMed     Text format     Abstract available

  40. CHLEBOWSKI RT, Luo J, Anderson GL, Barrington W, et al
    Weight loss and breast cancer incidence in postmenopausal women.
    Cancer. 2018 Oct 8. doi: 10.1002/cncr.31687.
    PubMed     Text format     Abstract available

  41. ROMANOFF A, Zabor EC, Petruolo O, Stempel M, et al
    Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31757.
    PubMed     Text format     Abstract available


    Cancer Res

  42. WANG Z, Grosskurth SE, Cheung T, Petteruti P, et al
    Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-1362.
    PubMed     Text format     Abstract available

  43. ALI R, Al-Kawaz A, Toss MS, Green AR, et al
    Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0633.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  44. BERHILI S, Ouabdelmoumen A, Sbai A, Kebdani T, et al
    Radical Mastectomy Increases Psychological Distress in Young Breast Cancer Patients: Results of A Cross-sectional Study.
    Clin Breast Cancer. 2018 Aug 31. pii: S1526-8209(18)30522.
    PubMed     Text format     Abstract available

  45. SHAKER OG, Senousy MA
    Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women.
    Clin Breast Cancer. 2018 Sep 19. pii: S1526-8209(18)30444.
    PubMed     Text format     Abstract available

  46. WATSON GA, Deac O, Aslam R, O'Dwyer R, et al
    Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.
    Clin Breast Cancer. 2018 Sep 8. pii: S1526-8209(18)30507.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  47. ABOUTALIB SS, Mohamed AA, Berg WA, Zuley ML, et al
    Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening.
    Clin Cancer Res. 2018 Oct 11. pii: 1078-0432.CCR-18-1115.
    PubMed     Text format     Abstract available


    Eur J Cancer

  48. CRISTOFANILLI M, DeMichele A, Giorgetti C, Turner NC, et al
    Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Eur J Cancer. 2018;104:21-31.
    PubMed     Text format     Abstract available


    Gene

  49. SHI S, Chen X, Liu H, Yu K, et al
    LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/beta-catenin pathway.
    Gene. 2018 Oct 6. pii: S0378-1119(18)31039-4. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available


    Histopathology

  50. RAGHAVENDRA A, Kalita-de Croft P, Vargas AC, Smart CE, et al
    Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.
    Histopathology. 2018;73:68-80.
    PubMed     Text format     Abstract available


    Int J Cancer

  51. GIRARD E, Eon-Marchais S, Olaso R, Renault AL, et al
    Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31921.
    PubMed     Text format     Abstract available

  52. BERRANDOU T, Mulot C, Cordina-Duverger E, Arveux P, et al
    Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: a gene-set analysis.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31917.
    PubMed     Text format     Abstract available

  53. LATTOUF H, Kassem L, Jacquemetton J, Choucair A, et al
    LKB1 regulates PRMT5 activity in breast cancer.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31909.
    PubMed     Text format     Abstract available

  54. SHEN Y, Zhang W, Liu J, He J, et al
    Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  55. MIGNOT F, Loirat D, Dureau S, Bataillon G, et al
    Disseminated tumor cells predict efficacy of regional nodal irradiation in early stage breast cancer.
    Int J Radiat Oncol Biol Phys. 2018 Oct 3. pii: S0360-3016(18)33813.
    PubMed     Text format     Abstract available


    J Clin Invest

  56. KUMAR S, Wilkes DW, Samuel N, Blanco MA, et al
    DeltaNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
    J Clin Invest. 2018 Oct 8. pii: 99673. doi: 10.1172/JCI99673.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  57. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    PubMed     Text format     Abstract available

  58. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    PubMed     Text format     Abstract available

  59. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    PubMed     Text format    

  60. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    PubMed     Text format    


    J Surg Oncol

  61. BEAR HD, Wan W, Robidoux A, Rubin P, et al
    Re: Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):917-923.
    J Surg Oncol. 2018;118:722.
    PubMed     Text format    


    N Engl J Med

  62. KANAKIS GA, Jorgensen N, Goulis DG
    Breast Cancer in Men.
    N Engl J Med. 2018;379:1385.
    PubMed     Text format    


    Oncology

  63. RESENDE U, Cabello C, Oliveira Botelho Ramalho S, Zeferino LC, et al
    Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma.
    Oncology. 2018;95:229-238.
    PubMed     Text format     Abstract available


    PLoS One

  64. ZUGNI F, Ruju F, Pricolo P, Alessi S, et al
    The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.
    PLoS One. 2018;13:e0205251.
    PubMed     Text format     Abstract available

  65. HARANO K, Wang Y, Lim B, Seitz RS, et al
    Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
    PLoS One. 2018;13:e0204513.
    PubMed     Text format     Abstract available

  66. VAN TREUREN T, Vishwanatha JK
    CRISPR deletion of MIEN1 in breast cancer cells.
    PLoS One. 2018;13:e0204976.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  67. CHU B, He A, Tian Y, He W, et al
    Photoaffinity-engineered protein scaffold for systematically exploring native phosphotyrosine signaling complexes in tumor samples.
    Proc Natl Acad Sci U S A. 2018;115:E8863-E8872.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: